TP53 and myelodysplastic syndrome: Emphasizing molecular features, tissue architecture, and histological appearance, WHO-2022 classification introduced new categories, including MDS with biallelic TP53 inactivation (MDS-biTP53), hypoplastic MDS (MDS-h), and MDS with fibrosis (MDS-f) [10].